In California, BioMADE announced an agreement with Lygos to acquire Lygos’ pilot-scale biomanufacturing facility in Hayward, California, and operate it as a multi-user national asset. This facility, aiming to open by early 2026, will serve as the second site in BioMADE’s network aimed at expanding domestic bioindustrial manufacturing capabilities and strengthening supply chains. The US biomanufacturing industry faces a critical lack of scale-up infrastructure, often leading companies to seek facilities overseas and risk IP loss. The acquisition allows Lygos to focus on commercialization while providing broader access to advanced infrastructure. The facility is nearly 25,000 sq ft, includes processing and analytical space, and will see further investment from BioMADE, supported by at least $80M from the U.S. Department of Defense. It will support production for defense materials and consumer products.
More on the story.
